Intra-lymph node injection of polymer scaffolds for targeted cancer immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapy methods face challenges in efficiently targeting lymph nodes and tumors, leading to inadequate immune responses due to systemic injection limitations and toxicity concerns, necessitating a more precise and localized approach for antigen and adjuvant delivery.
Innovation Solution
Intra-lymph node injection of polymer scaffolds containing cancer antigens and adjuvants, such as toll-like receptor agonists, to directly activate immune responses within lymph nodes, bypassing systemic distribution and toxicity issues, with controlled release and spatial localization to enhance tumor-specific immune cell generation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic injection methods are used to deliver cancer antigens and adjuvants, then the immune response can be activated, but the delivery efficiency to lymph nodes is insufficient and toxicity increases
Solution Approach 1:
The patent extracts the immune activation function from systemic circulation and relocates it directly to the lymph node environment. By injecting antigens and adjuvants directly into lymph nodes, the system eliminates the need for systemic distribution, thereby reducing toxicity while maintaining immune response activation. This is achieved through direct intra-lymph node injection techniques that deliver therapeutic agents precisely to the target site.
Solution Approach 2:
The patent introduces lymph nodes as an intermediary target site between systemic injection and tumor cells. By delivering antigens and adjuvants directly to lymph nodes first, the system creates a controlled environment for immune activation before the activated immune cells are recruited to tumors. This intermediary approach reduces systemic exposure to toxic agents while ensuring effective immune response generation.
2Reliability
If systemic injection is used for antigen and adjuvant delivery, then immune response can be elicited, but the precision and localization of immune signal integration is inadequate
Solution Approach 1:
The patent applies local quality by creating distinct functional zones within lymph nodes through targeted delivery. Different regions of the lymph node receive specific combinations of antigens and adjuvants, allowing for spatially controlled immune signal integration. This enables precise localization of immune activation events within the lymph node architecture, improving the precision of immune response generation while reducing systemic effects.
Data Source
AI summary
The present disclosure relates to methods for eliciting an immune response to a cancer antigen in a subject in need thereof by introducing directly into at least one lymph node of the subject, and preferably at least two lymph nodes, a therapeutically effective amount of a cancer antigen and/or an adjuvant such that an immune response to the cancer antigen is activated or enhanced in the subject. The present disclosure also concerns pharmaceutical compositions that comprise a therapeutically effective amount of a cancer antigen and/or an adjuvant capable of mediating, and more preferably enhancing, activation of the immune system of a subject against cancer cells that are associated with any of a variety of cancers. The disclosure also relates to the use of such pharmaceutical compositions in the treatment or prevention of a cancer in a recipient subject.